据报告,Johnson & Johnson打算以约100亿美元购买宫内治疗药物。 Johnson & Johnson is reportedly set to acquire Intra-Cellular Therapies for around $10 billion.

据报告,Johnson & Johnson正在谈判获得大约100亿美元的宫内治疗药物,重点是治疗中枢神经系统紊乱的治疗方法。 Johnson & Johnson is reportedly in talks to acquire Intra-Cellular Therapies for around $10 billion, focusing on the latter's treatments for central nervous system disorders. 这一潜在交易本周一结束就可完成,标志着J&J在2024年保健交易出现萧条之后恢复了重大收购。 The potential deal could be finalized as soon as this week, marking J&J's return to major acquisitions following a 2024 slump in healthcare transactions. Intra-Cellular 的股价去年上涨了约 40%。 Intra-Cellular's shares have risen about 40% in the last year.